Clinical and pathological response after neoadjuvant chemotherapy with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer

被引：0
|
作者：
Charehbili, A. [1 ]
Van de Ven, S. [1 ]
Liefers, G. J. [1 ]
Smit, V. T. [1 ]
Wasser, M. N. [1 ]
Kranenbarg, E. M. Meershoek-Klein [1 ]
Van Leeuwen-Stok, A. E. [2 ]
Van de Velde, C. J. H. [1 ]
Nortier, J. W. R. [1 ]
Kroep, J. R. [1 ]
机构：
[1] Leiden Univ, Med Ctr, Leiden, Netherlands
[2] Dutch Breast Canc Trialists Grp BOOG, Leiden, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1858
引用
收藏
页码：S401 / S401
页数：1
相关论文
共 50 条
  • [11] Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
    Stefanie de Groot
    Hanno Pijl
    Ayoub Charehbili
    Saskia van de Ven
    Vincent T. H. B. M. Smit
    Elma Meershoek-Klein Kranenbarg
    Joan B. Heijns
    Laurence J. C. van Warmerdam
    Lonneke W. Kessels
    M. Wouter Dercksen
    Manon J. A. E. Pepels
    Hanneke W. M. van Laarhoven
    Birgit E. P. J. Vriens
    Hein Putter
    Marta Fiocco
    Gerrit-Jan Liefers
    Jacobus J. M. van der Hoeven
    Johan W. R. Nortier
    Judith R. Kroep
    Breast Cancer Research, 21
  • [12] Randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer
    Kohno, Norio
    Hasegawa, Yoshie
    Horiguchi, Jun
    Ishikawa, Takashi
    Miura, Daishu
    Hayashi, Mitsuhiro
    Takao, Shintaro
    Kim, Seung Jin
    Tanino, Hirokazu
    Akazawa, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [13] Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran
    Roudini, Kamran
    Mirzania, Mehrzad
    Yavari, Tahereh
    Seyyedsalehi, Monireh Sadat
    Nahvijou, Azin
    Zebardast, Jayran
    Saadat, Mina
    Khajeh-Mehrizi, Ahmad
    ARCHIVES OF IRANIAN MEDICINE, 2024, 27 (04) : 206 - 215
  • [14] Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer
    Spring, L. M.
    Han, H.
    Hamilton, E.
    Irie, H.
    Santa-Maria, C. A.
    Reeves, J.
    Pan, P.
    Shan, M.
    Tang, Y.
    Graham, J. R.
    Hazard, S.
    Ellisen, L. W.
    Isakoff, S. J.
    BREAST, 2021, 56 : S55 - S56
  • [15] Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
    Lucas, Mairi W.
    Kelly, Catherine M.
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2493 - 2506
  • [16] A predictor model for pathological CR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer
    Fujiki, Yoshitaka
    Yamamoto, Yutaka
    Tomiguchi, Mai
    Sueta, Aiko
    Takeshita, Takashi
    Ibusuki, Mutsuko
    Iwase, Hirotaka
    CANCER SCIENCE, 2018, 109 : 654 - 654
  • [17] A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer.
    Horiguchi, Jun
    Hasegawa, Yoshie
    Miura, Daishu
    Ishikawa, Takashi
    Hayashi, Mitsuhiro
    Takao, Shintaro
    Kim, Seung Jin
    Tanino, Hirokazu
    Miyashita, Masaru
    Konishi, Muneharu
    Shigeoka, Yasushi
    Yamagami, Kazuhiko
    Akazawa, Kohei
    Kohno, Norio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [18] Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
    Laura M. Spring
    Hyo Han
    Minetta C. Liu
    Erika Hamilton
    Hanna Irie
    Cesar A. Santa-Maria
    James Reeves
    Peng Pan
    Ming Shan
    Yongqiang Tang
    Julie R. Graham
    Sebastien Hazard
    Leif W. Ellisen
    Steven J. Isakoff
    Nature Cancer, 2022, 3 : 927 - 931
  • [19] Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
    Spring, Laura M.
    Han, Hyo
    Liu, Minetta C.
    Hamilton, Erika
    Irie, Hanna
    Santa-Maria, Cesar A.
    Reeves, James
    Pan, Peng
    Shan, Ming
    Tang, Yongqiang
    Graham, Julie R.
    Hazard, Sebastien
    Ellisen, Leif W.
    Isakoff, Steven J.
    NATURE CANCER, 2022, 3 (08) : 927 - +
  • [20] An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
    Chung, Wai-Shan
    Chen, Shin-Cheh
    Ko, Tai-Ming
    Lin, Yung-Chang
    Lin, Sheng-Hsuan
    Lo, Yung-Feng
    Tseng, Shu-Chi
    Yu, Chi-Chang
    CANCERS, 2022, 14 (17)
12345